Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Heather Friberg

Showing results (31-40 of 43) with videos related to

Pageof 5
Sort By:
Plos Pathogens|October 31, 2024
B cell receptor dependent enhancement of dengue virus infectionChad Gebo, Céline S C Hardy, Benjamin D McElvany, et al.
The Journal of Infectious Diseases|November 23, 2019
The Effects of Japanese Encephalitis Vaccine and Accelerated Dosing Scheduling on the Immunogenicity of the Chimeric Yellow Fever Derived Tetravalent Dengue Vaccine: A Phase II, Randomized, Open-Label, Single-Center Trial in Adults Aged 18 to 45 Years in the United StatesAaron Glass, Mark Polhemus, Dongliang Wang, et al.
Plos Pathogens|January 29, 2021
Temporally integrated single cell RNA sequencing analysis of PBMC from experimental and natural primary human DENV-1 infectionsAdam T Waickman, Heather Friberg, Gregory D Gromowski, et al.
NPJ Vaccines|October 17, 2024
Long term T cell response and safety of a tetravalent dengue vaccine in healthy childrenSanja Mandaric, Heather Friberg, Xavier Saez-Llorens, et al.
The American Journal of Tropical Medicine and Hygiene|April 29, 2020
Safety and Immunogenicity of an AS03<sub>B</sub>-Adjuvanted Inactivated Tetravalent Dengue Virus Vaccine Administered on Varying Schedules to Healthy U.S. Adults: A Phase 1/2 Randomized StudyLeyi Lin, Kirsten E Lyke, Michael Koren, et al.
The American Journal of Tropical Medicine and Hygiene|July 8, 2015
Safety and Immunogenicity of a Dengue Virus Serotype-1 Purified-Inactivated Vaccine: Results of a Phase 1 Clinical TrialLuis Javier Martinez, Leyi Lin, Jason M Blaylock, et al.
The Journal of Infectious Diseases|September 23, 2020
Immunogenicity of a Live-Attenuated Dengue Vaccine Using a Heterologous Prime-Boost Strategy in a Phase 1 Randomized Clinical TrialLeyi Lin, Michael A Koren, Kristopher M Paolino, et al.
NPJ Vaccines|May 22, 2021
Enhanced dengue vaccine virus replication and neutralizing antibody responses in immune primed rhesus macaquesMichael K McCracken, Caitlin H Kuklis, Chandrika B Kannadka, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 27, 2026
Long-term antibody dynamics challenge the paradigm of lifelong homotypic immunity to dengue virusJair Andrade, Adrien Mitard de Girardier, Angkana T Huang, et al.
The Journal of Infectious Diseases|June 24, 2020
A Phase 1, Open-Label Assessment of a Dengue Virus-1 Live Virus Human Challenge StrainTimothy P Endy, Dongliang Wang, Mark E Polhemus, et al.
Pageof 5

Showing results (31-40 of 43) with videos related to

Sort By:
Pageof 5
Plos Pathogens|October 31, 2024
B cell receptor dependent enhancement of dengue virus infectionChad Gebo, Céline S C Hardy, Benjamin D McElvany, et al.
The Journal of Infectious Diseases|November 23, 2019
The Effects of Japanese Encephalitis Vaccine and Accelerated Dosing Scheduling on the Immunogenicity of the Chimeric Yellow Fever Derived Tetravalent Dengue Vaccine: A Phase II, Randomized, Open-Label, Single-Center Trial in Adults Aged 18 to 45 Years in the United StatesAaron Glass, Mark Polhemus, Dongliang Wang, et al.
Plos Pathogens|January 29, 2021
Temporally integrated single cell RNA sequencing analysis of PBMC from experimental and natural primary human DENV-1 infectionsAdam T Waickman, Heather Friberg, Gregory D Gromowski, et al.
NPJ Vaccines|October 17, 2024
Long term T cell response and safety of a tetravalent dengue vaccine in healthy childrenSanja Mandaric, Heather Friberg, Xavier Saez-Llorens, et al.
The American Journal of Tropical Medicine and Hygiene|April 29, 2020
Safety and Immunogenicity of an AS03<sub>B</sub>-Adjuvanted Inactivated Tetravalent Dengue Virus Vaccine Administered on Varying Schedules to Healthy U.S. Adults: A Phase 1/2 Randomized StudyLeyi Lin, Kirsten E Lyke, Michael Koren, et al.
The American Journal of Tropical Medicine and Hygiene|July 8, 2015
Safety and Immunogenicity of a Dengue Virus Serotype-1 Purified-Inactivated Vaccine: Results of a Phase 1 Clinical TrialLuis Javier Martinez, Leyi Lin, Jason M Blaylock, et al.
The Journal of Infectious Diseases|September 23, 2020
Immunogenicity of a Live-Attenuated Dengue Vaccine Using a Heterologous Prime-Boost Strategy in a Phase 1 Randomized Clinical TrialLeyi Lin, Michael A Koren, Kristopher M Paolino, et al.
NPJ Vaccines|May 22, 2021
Enhanced dengue vaccine virus replication and neutralizing antibody responses in immune primed rhesus macaquesMichael K McCracken, Caitlin H Kuklis, Chandrika B Kannadka, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 27, 2026
Long-term antibody dynamics challenge the paradigm of lifelong homotypic immunity to dengue virusJair Andrade, Adrien Mitard de Girardier, Angkana T Huang, et al.
The Journal of Infectious Diseases|June 24, 2020
A Phase 1, Open-Label Assessment of a Dengue Virus-1 Live Virus Human Challenge StrainTimothy P Endy, Dongliang Wang, Mark E Polhemus, et al.
Pageof 5